Generic Name and Formulations:
Dantrolene sodium 20mg; per vial; lyophilized pwd for IV inj after reconstitution; contains mannitol.
US WorldMeds, LLC
Indications for REVONTO:
Management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia (MH). Prevention of malignant hyperthermia in susceptible patients during pre-op or sometimes post-op.
Adults and Children:
Treatment: Give by rapid IV push at a minimum of 1mg/kg, continue until symptoms subside or max cumulative dose of 10mg/kg has been reached; if physiologic and metabolic abnormalities reappear, repeat regimen. Prevention: Start approx. 75 mins prior to anesthesia, give 2.5mg/kg by IV infusion over 1hr; may give additional doses during anesthesia or prolonged surgery.
Institute supportive measures (eg, discontinue MH-triggering agents, increase oxygen requirements, manage metabolic acidosis, cooling if necessary, monitor urinary output and electrolyte imbalance). Monitor for skeletal muscle weakness, difficulty swallowing and choking. Increased risk of hepatic injury (esp. in females or patients >35yrs of age); monitor hepatic function frequently (eg, SGOT, SGPT). Avoid extravasation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid MH-triggering agents. Concomitant calcium channel blockers (eg, verapamil): not recommended. Caution with concomitant tranquilizers. May potentiate vecuronium-induced neuromuscular block. Protein binding reduced by warfarin or clofibrate; and increased by tolbutamide.
Muscle relaxant (skeletal).
Loss of grip strength, weakness in the legs, drowsiness, dizziness, thrombophlebitis, tissue necrosis secondary to extravasation, inj site reactions (eg, pain, erythema, swelling); rare: pulmonary edema, urticaria, erythema.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|